Megakaryocytopoiesis and platelet production can be assessed with reasonable accuracy by quantitative and functional analyses of circulating platelets. The evaluation of megakaryocytopoiesis in culture has remained unsatisfactory, particularly because platelet production is rarely observed. In mouse culture systems, megakaryocytes have been identified almost entirely by measurements of acetyl cholinesterase, size, and ploidy without concomitant assessment of maturation based on such criteria as the formation of granules, demarcation membranes, and cytoplasmic fragmentation. The availability of various thrombopoietic cytokines, in particular thrombopoietin (TPO), and their imminent clinical use has made a more detailed understanding of their effect on differentiation and maturation of the MK A FTER MANY YEARS and studies by numerous investigators, the existence of a thrombopoiesis-stimulating hormone, here called thrombopoietin ( P O ) , has become a reality. Details of its cellular biology have been reviewed recently.' Its genomic structure, chromosome localization, and biomolecular synthesis are being rapidly defined in several species, including man.2-5 As is usually the case, new insights raise new questions. In the case of TPO, questions related to its specific biologic function, the state of differentiation of its target cells, and the possible synergism with other hematopoietic cytokines are of particular importance because of the predictable impact the availability of this hormone will have in the clinical arena. Among other cytokines, interleukin (IL)-3, IL-6, IL-11, leukemia inhibitory factor (LIF), and kit ligand (KL) have also been reported to promote megakaryocyte proliferation in vitro and to increase the peripheral blood platelet count in rodents, dogs, and nonhuman primate^.^.'^ One of the questions is whether some or all of these cytokines are dispensible for the production of normal megakaryocytes (MK), ie, whether TPO alone may be sufficient for the normal development of this cell lineage and its progeny.
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To date, the bulk of our studies have been conducted in an in vitro murine system in which the proliferation of megakaryocytic progenitors has been scored by detection of acetylcholinesterase (AChE) together with cell sizing and ploidy analyse^.'^*'^ It is clear, however, that A C E appears very early after commitment to the MK lineage and that neither the quantitation of this enzyme, nor the size or ploidy of the proliferating cells are necessarily indicative of normal MK development leading to platelet production. In fact, although determination of AChE in the murine system has proven to be extremely useful for the recognition of MK precursors, which could not otherwise be identified, it should be realized that neither the subcellular localization of this marker nor its relevance to cellular maturation have been determined. Among other features, normal MK development requires the generation of alpha granules, the formation of platelet temtories and cytoplasmic fragmentation, which can only be demonstrated on the ultrastructural le~e1.".'~ While preliminary electron microscopic studies have to a large extent substantiated the salutary effect of TPO on megakaryo-and thrombocytopoiesis, the extraordinary degree of blebbing seen by light microscopy of mature megakaryocytes when Tpo is added to cultures in vitro'.'' also raises a second question, namely whether such TPO-induced cells are activated. Such a finding would not only promote hemostasis, but could also lead to thrombosis. Even the demonstration that mice made genetically deficient for the TPO receptor, c-Mpl, have circulating platelets, which seem to function by aggregometric criteria," does not permit the conclusion that they are normal platelets. For all these reasons, it seemed prudent to perform in-depth ultrastructural analyses on mouse bone marrow cultures grown in the presence of TPO alone, TPO plus a variety of cytokines, as well as under conditions in which TPO or other cytokines were competitively blocked with neutralizing reagents. Our studies suggest that although cytokines that use the a130 receptor subunit can augment the proliferation and terminal differentiation of MK, they appear not to be absolutely essential. Moreover, IL-1 1 failed to support the full cytoplasmic maturation of megakaryocyte granules and membranes in the absence of endogenous T P O . In contrast, TPO alone is able to drive full MK development, in that, even when the effect of other cytokines is neutralized, in its presence, the cells recapitulate the entire spectrum of normal murine megakaryocytopoiesis seen in vivo. #3-85/35xx) to eliminate mature megakaryocytes.
The absence of recognizable MK in the starting cell suspension was established hy light microscopy. The cells were washed in phosphate-buffered saline (PBS) and resuspended at IO" cells/mL in serum-free minimal essential medium (MEM) supplemented with 1% Nutridoma-SP medium (Boehringer Mannheim, Indianapolis, IN) essentially as described previously.'5 Clearly. such specimens contain cells. which may already be committed to the MK lineage. as well as other bone marrow cells capable of elaborating a variety of cytokines and growth factors.
TPO was obtained as the serum-free culture supernatant of baby hamster kidney (BHK) cells expressing the corresponding cDNAs essentially as described elsewhere. '5 Soluble Mpl receptor (S-Mpl) was produced by introduction of a stop codon into the cDNA just upstream of the transmembrane domain and replacing it with a poly (His) sequence. The recombinant protein was then purified by affinity chromatography over Ni"-agarose. The other cytokines were obtained commercially as reported in detail before." The anti-gp 130 antibody (RX187) was kindly provided by Drs T a p and Kishimoto (Osaka University, Osaka. Japan)." It was used at a concentration of 0.29. The cultures were grown in a humidified atmosphere containing 5% COz. All cultures were terminated after 5 days when For personal use only. on May 31, 2017. by guest www.bloodjournal.org From Electron microscopy. After fixation in 3% phosphate buffered glutaraldehyde, the specimens were stored from 2 days to 2 weeks. Because they were extremely small, centrifugation at 8SOOg was necessary at each step of the dehydration and embedding procedures. In some instances, erythrocytes were added to the fixed specimens to facilitate their transfer and to lessen the centrifugal force necessary to pellet the cells. Such maneuvers have proven to assure good ultrastructural preservation of small specimens in previous studies. The specimens were postfixed in osmium tetroxide, dehydrated in increasing concentrations of alcohol and propylene oxide, and embedded in PolyBed 812. Thin sections for electron microscopy were stained with uranyl acetate and lead citrate. To evaluate the degree of granulation, thick sections (1 pm) were stained with toluidine blue and viewed by light microscopy. A total of 1 l1 specimens were subjected to electron microscopy. Each experiment was conducted in duplicate or triplicate, and a minimum of 50 megakaryocytes were identified in each block by an observer requested to record a description of cell structure without having been informed of the relevant experimental protocol.
RESULTS
To determine the morphologic effects of TPO and other cytokines on MK, which were grown for 5 days in a serumfree liquid medium, control cultured MK were first compared with freshly isolated cells ( Figs 1A and B) . Without addition of any exogenous cytokines, MK were difficult to find. However, when found, they were easily recognized as differentiated, mature megakaryocytes exhibiting demarcation membranes and platelet territories (Fig 1B) . The autophagic vacuoles believed to be formed by granule to granule fusion are considered irrelevant culture artifacts as they are seen in practically all cultures grown in serum free Nutridoma containing media in our own laboratory, as well as in others.23 The addition of IL-3 (200 ng/mL,) markedly expanded all cell types including the population of A C E positive cells.15 For this reason, most of the ultrastructural analyses and AChE activity determinations were performed on specimens containing IL-3 with or without the addition of cytokines and/or inhibitors. Because this particular culture system includes other bone marrow and stromal cells, which could potentially contribute TPO as well as other cytokines to the medium, W O was competitively neutralized ence of IL-3 alone, or with the addition of S-Mpl, anti-gpl30, and both of these inhibitors in the presence or absence of Tpo. It is clear that simultaneous neutralization of TPO and cytokines whose signal transducing effect depends on gp130 all but abolished the differentiation of cells containing the AChE marker (Fig 2, column 4) , whereas, the addition of TPO-even in the presence of anti-gpl30, induced a considerable increase in AchE (Fig 2, column 5) . Interestingly, under the prevailing conditions, with only AChE activity used as a yardstick, anti-gpl30 appeared to be more inhibitory than sMpl, if no exogenous TPO was added to the cultures. Although the neutralization of gpl30-linked cytokines seemed to reduce cell proliferation in general, as based on relative AChE activity, as long as the culture medium contained TPO whether "spontaneously" elaborated or added to the medium, such inhibition appeared to have no noteworthy effect on the differentiation or maturation of megakaryocytes, as determined ultrastructurally (Figs 3 and 4) . Neutralization of IL-3 or KL failed to affect MK differentiation (data not shown). In fact, whether the cells were grown in the presence of TPO alone, IL-3 + WO, IL-6 alone, or IL-11 + TPO, the presence of anti-gpl30 in the medium did not impact on the differentiation or terminal maturation of MK, at least as assessed ultrastructurally. It seems of interest that in specimens cultured with L-3, IL-l l, and sMpl, a small number of large megakaryocytes were identified. Here, the impression was gained that such cells were poorly granulated and that there was random organization of demarcation membranes resulting in fragments of cytoplasm, which were not recognizable as platelet territories because of the absence of organelles (Figs 5 and 6) . Most striking was the observation that the addition of S-Mpl plus anti-gpl30 resulted in complete growth arrest of the MK lineage (Fig 7) . Low power surveys (magnification X 2,000) of hundreds of cells in such specimens did not lead to the detection of any cells that could be identified as megakaryocytes.
This correlated well with the low level of AChE activity. On a strictly morphological basis, the cells would be classified as monocytedmacrophages or granulocyte precursors. They were reminiscent of cells seen in bone manow specimens of patients whose marrow has undergone maturation arrest without compensatory blastocytosis and with complete absence of megakaryocytes.
with soluble Mpl (S-Mpl), and cytokines that use the gp130 transmembrane receptor were inhibited by addition of murine anti gp130, both separately and in combination. Figure  2 reThe present studies were designed to determine the role cords the relative AChE activity of cells cultured in the presof a number of cytokines on the process of megakaryocyto- For personal use only. on May 31, 2017. by guest www.bloodjournal.org From poiesis. As the crucial steps in this process are characterized primarily by morphologic criteria,".'' we applied electron microscopy to observe granule formation, the development of demarcation membranes, and platelet field formation, as well as the extent of cytoplasmic fragmentation. Because this particular culture system contains cells belonging to other lineages including stromal cells that are potentially capable of elaborating megakaryocytopoietic cytokines, a neutralizing monoclonal antibody directed against the gpl30-related cytokines IL-6, IL-1 I , LIF, as well as a soluble form of the thrombopoietin receptor, S-Mpl were used to study the contributions of each cytokine individually, thereby negating the potential effect of such factors contributed to the medium by other cells. On the basis of AChE measurements alone, it appears as though anti-gp130 had a greater effect on inhibiting MK development than sol Mpl (Fig 2) . It should be realized, however, that AchE determinations have not been correlated with cytoplasmic differentiation or maturation, as this enzyme has not been localized subcellularly. The greater effect of anti-gpl30 than of sol Mpl in the IL-3 only cultures may be attributable to "endogenous" cytokines, such as IL-6, IL-11, or KL. In the presence of exogenous TPO anti-gp 130 seemed to have little or no effect (Fig 2, column 5 ) ; the cells displayed characteristic granules. demarcation membranes, and platelet fields ( Figs   3 and 4) . Thus, the data presented here suggest that hematopoietic growth factors whose shared signal transduction unit is inhibitable with anti-gp130 are not necessarily required for the proliferation or terminal differentiation of the cells. This is in good agreement with the results of other studies performed in our laboratory in which purified human CD34' progenitors had an absolute requirement for TPO to develop into mature megakaryocytes (Murray W, Bruno E, ZuckerFranklin D, Ho A, and Hoffman R, (submitted). In the present studies, there was a complete lack of normal cytoplasmic maturation when the effects of endogenous (or induced) TPO was eliminated, even though IL-3 increased the relative level of AChE (Fig 7) . Of considerable interest were the megakaryocytes observed in a specimen grown in the presence of IL-3, IL-l I . and S-Mpl (Figs 5 and 6 ). Although these cells had attained the size of megakaryocytes, they had very few granules and seemed excessively fragmented. These fragments could not be considered platelet territories because they were devoid of platelet-specific organelles (Fig 6) . Thus, the beneficial effect of IL-6 or IL-l I on platelet production in vivo are likely to be either dependent on TPO. or secondary to its induction. Several attempts to identify TPO in IL-6-stimulated marrow cell suspension cultures failed using a BaF3/mpl biological assay (unpublished observation, 1995). Resolution of this issue will require the development of a sensitive enzyme-linked immunosorbent assay (ELISA) for TPO. It is, however, clear that TPO can act in the absence of these other cytokines.
The arguments voiced above do not necessarily negate the possibility that IL-6 or IL-l1 may have an important synergistic effect in vivo. The release of acute phase reactants is usually followed by an increase in the platelet For personal use only. on May 31, 2017. by guest www.bloodjournal.org From count, whether or not this is beneficial to the organism. It has also been well recognized that acute blood loss or platelet destruction by direct or immunologic mechanisms is likely to increase levels of acute phase reactants including IL-6 and IL-11, as well as the availability of TPO. While the administration of IL-6 to intact animals temporarily increases megakaryocytopoiesis, as well as the peripheral platelet count, its effect may be inj~rious.'~ On the other hand, administration of IL-l1 seems to stimulate normal megakaryocyte and platelet production.2' At the present time, it is difficult to evaluate whether the in vivo effect of IL-I l is mediated through TPO, at least in part. The present in vitro studies showed an effect of IL-I 1 even when TPO was inhibited with S-Mpl. Conceivably, this cytokine may play some important role under certain conditions of accelerated thrombocytopoiesis. Be that as it may, the observations reported here seem compatible with the concept that, during normal homeostasis, megakaryocyte differentiation and platelet levels can be maintained by TPO alone. Therefore, it has become clear that TPO is the primary regulator of megakaryocyte development. While the addition of IL-3, IL-6, or IL-1 1 may augment the proliferative response of the bone marrow in general, as well as that within the MK lineage, these cytokines have a multiplicity of targets and effects that may not always be desirable when the primary therapeutic goal is an increase of platelet production. Only clinical trials directly comparing these agents will provide answers to these questions.
